IL4 and asthma: Biologic drugs, such as anti-IgE and anti-IL-5, anti-IL-4/IL-13 monoclonal antibodies, are currently being used with clinical success in patients with type-2 diseases, such as asthma and CRSwNP [2], and only recently some authors [12] suggested their efficacy also in the treatment of comorbid EOM.